These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 38044039)

  • 1. Changing from NAFLD to MASLD: Similar cumulative incidence of reflux esophagitis between NAFLD and MASLD.
    Fukunaga S; Mukasa M; Nakano D; Tsutsumi T; Kawaguchi T
    Clin Mol Hepatol; 2024 Jan; 30(1):121-123. PubMed ID: 38044039
    [No Abstract]   [Full Text] [Related]  

  • 2. Non-alcoholic fatty liver disease and the development of reflux esophagitis: A cohort study.
    Min YW; Kim Y; Gwak GY; Gu S; Kang D; Cho SJ; Guallar E; Cho J; Sinn DH
    J Gastroenterol Hepatol; 2018 May; 33(5):1053-1058. PubMed ID: 29131401
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nonalcoholic Fatty Liver Disease Is Associated with Increased Risk of Reflux Esophagitis.
    Yang HJ; Chang Y; Park SK; Jung YS; Park JH; Park DI; Cho YK; Ryu S; Sohn CI
    Dig Dis Sci; 2017 Dec; 62(12):3605-3613. PubMed ID: 29063416
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Increased risk of reflux esophagitis in non-obese individuals with nonalcoholic fatty liver disease: a cross-sectional study.
    Qiu P; Du J; Zhang C; Li M; Li H; Chen C
    Ann Med; 2023; 55(2):2294933. PubMed ID: 38109930
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Implications of the new nomenclature of steatotic liver disease and definition of metabolic dysfunction-associated steatotic liver disease.
    Loomba R; Wong VW
    Aliment Pharmacol Ther; 2024 Jan; 59(2):150-156. PubMed ID: 38153279
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Insulin resistance and central obesity determine hepatic steatosis and explain cardiovascular risk in steatotic liver disease.
    Semmler G; Balcar L; Wernly S; Völkerer A; Semmler L; Hauptmann L; Wernly B; Aigner E; Niederseer D; Datz C
    Front Endocrinol (Lausanne); 2023; 14():1244405. PubMed ID: 37842290
    [TBL] [Abstract][Full Text] [Related]  

  • 7. From nonalcoholic steatohepatitis, metabolic dysfunction-associated fatty liver disease, to steatotic liver disease: Updates of nomenclature and impact on clinical trials.
    Yeh ML; Yu ML
    Clin Mol Hepatol; 2023 Oct; 29(4):969-972. PubMed ID: 37718552
    [No Abstract]   [Full Text] [Related]  

  • 8. Exploring the landscape of steatotic liver disease in the general US population.
    Ciardullo S; Carbone M; Invernizzi P; Perseghin G
    Liver Int; 2023 Nov; 43(11):2425-2433. PubMed ID: 37592856
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Waiting for the changes after the adoption of steatotic liver disease.
    Yoon EL; Jun DW
    Clin Mol Hepatol; 2023 Oct; 29(4):844-850. PubMed ID: 37670441
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nonalcoholic fatty liver disease increases the risk of gastroesophageal reflux disease: A systematic review and meta-analysis.
    Xue J; Xin H; Ren N; Zhou C; Yang J; Song L; Qin S
    Eur J Clin Invest; 2019 Sep; 49(9):e13158. PubMed ID: 31338830
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Familial coaggregation of MASLD with hepatocellular carcinoma and adverse liver outcomes: Nationwide multigenerational cohort study.
    Ebrahimi F; Hagström H; Sun J; Bergman D; Shang Y; Yang W; Roelstraete B; Ludvigsson JF
    J Hepatol; 2023 Dec; 79(6):1374-1384. PubMed ID: 37647992
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Metabolic dysfunction-associated steatotic liver disease in older adults is associated with frailty and social disadvantage.
    Clayton-Chubb D; Kemp WW; Majeed A; Lubel JS; Woods RL; Tran C; Ryan J; Hodge A; Schneider HG; McNeil JJ; Roberts SK
    Liver Int; 2024 Jan; 44(1):39-51. PubMed ID: 37698034
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Circulating hormones in biopsy-proven steatotic liver disease and steatohepatitis: A Multicenter Observational Study.
    Valenzuela-Vallejo L; Chrysafi P; Kouvari M; Guatibonza-Garcia V; Mylonakis SC; Katsarou A; Verrastro O; Markakis G; Eslam M; Papatheodoridis G; Mingrone G; George J; Mantzoros CS
    Metabolism; 2023 Nov; 148():155694. PubMed ID: 37757973
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fatty Liver Disease: Enter the Metabolic Era.
    Wegermann K; Moylan C; Naggie S
    Curr HIV/AIDS Rep; 2023 Dec; 20(6):405-418. PubMed ID: 37882965
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association of Metabolic Dysfunction-Associated Steatotic Liver Disease/Non-alcoholic Fatty Liver Disease With Type 2 Diabetes Mellitus: A Case-Control Study in a Tertiary Care Hospital in Pakistan.
    Zahoor F; Saeed NU; Javed S; Sadiq HZ; Mand Khan F; Haider M; Shafqat MN; Maqbool A; Chaudhry A
    Cureus; 2023 Oct; 15(10):e47240. PubMed ID: 38021965
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Epidemiology of reflux disease and reflux esophagitis.
    Wienbeck M; Barnert J
    Scand J Gastroenterol Suppl; 1989; 156():7-13. PubMed ID: 2662390
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Brazilian evidence-based guideline for screening, diagnosis, treatment, and follow-up of metabolic dysfunction-associated steatotic liver disease (MASLD) in adult individuals with overweight or obesity: A joint position statement from the Brazilian Society of Endocrinology and Metabolism (SBEM), Brazilian Society of Hepatology (SBH), and Brazilian Association for the Study of Obesity and Metabolic Syndrome (Abeso).
    Moreira RO; Valerio CM; Villela-Nogueira CA; Cercato C; Gerchman F; Lottenberg AMP; Godoy-Matos AF; Oliveira RA; Brandão Mello CE; Álvares-da-Silva MR; Leite NC; Cotrim HP; Parisi ER; Silva GF; Miranda PAC; Halpern B; Pinto Oliveira C
    Arch Endocrinol Metab; 2023 Nov; 67(6):e230123. PubMed ID: 38048417
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A prospective study on the prevalence of MASLD in people with type-2 diabetes in the community. Cost effectiveness of screening strategies.
    Forlano R; Stanic T; Jayawardana S; Mullish BH; Yee M; Mossialos E; Goldin R; Petta S; Tsochatzis E; Thursz M; Manousou P
    Liver Int; 2024 Jan; 44(1):61-71. PubMed ID: 37718933
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Critical appraisal of metabolic dysfunction-associated steatotic liver disease: Implication of Janus-faced modernity.
    Kim GA; Moon JH; Kim W
    Clin Mol Hepatol; 2023 Oct; 29(4):831-843. PubMed ID: 37634892
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Steatotic liver disease, MASLD and risk of chronic kidney disease.
    Bilson J; Mantovani A; Byrne CD; Targher G
    Diabetes Metab; 2024 Jan; 50(1):101506. PubMed ID: 38141808
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.